OSSIO
Moshe Shneor has a diverse work experience spanning over 20 years. Moshe started their career at Ernst & Young, where they worked as a Senior Manager from July 2000 to December 2006. Moshe then joined Pollogen as CFO & COO in January 2007 and remained in that role until May 2015. Moshe Shneor then moved on to become the CEO of Pollogen subsidiary of Lumenis from June 2015 to December 2016. Currently, they hold the position of CFO at Ossio Ltd., a company focused on developing and commercializing osteoconductive fixation implants.
Moshe Shneor holds a CPA and MBA degree in Business Management from Tel Aviv University. The specific years of their education are not provided.
This person is not in any offices
OSSIO
OSSIO is an orthopedic fixation company committed to transforming the orthopedic experience for patients, physicians, and payors. Their vision is to provide the first credible replacement to metal implants in the $10B+ orthopedic fixation market (screws, pins, plates) with an Intelligent Bone Regeneration Technology. OSSIOfiber represents abreakthrough material platform for orthopedic and podiatric surgeons who seek a more biologically friendly way to restore patient stability and mobility with nothing permanent left behind.Founded in 2014, OSSIO began as the culmination of years of biomechanical research and a vision for the possibility of better bone healing. The technological basis of OSSIOfiber™ was developed and would lay the groundwork for ushering in a new breakthrough category of non-permanent fixation, “Bio-Integratives” hardware that has both desired strength AND bio-friendliness. Hardware that has the mechanical strength for easy insertion and secure fixation, while enabling the body to regrow bone, incorporating and replacing the implant (without the adverse inflammation and weakness often seen in “bio-resorbables and other “bio-composites”), has remained elusive to the industry until now.